Oral anticancer drugs: How limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1620-1629

  Prasad, Vinay ^a   Massey, Paul R ^b   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; CEDIRANIB; EVEROLIMUS; IMATINIB; PAZOPANIB; REGORAFENIB; SORAFENIB; SUNITINIB; TIVOZANIB; VANDETANIB; VEMURAFENIB;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DOSE RESPONSE; METHODOLOGY; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HUMANS; NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84903784229     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.0204     Document Type: Article

References (111)

1. Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419, 2013
2. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 30:134-141, 2012
3. Roland M, Torgerson DJ: What are pragmatic trials? BMJ 316:285, 1998
4. Houk BE, Bello CL, Poland B, et al: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemo Pharmacol 66:357-371, 2010
5. Rini BI, de La Motte Rouge T, Harzstark AL, et al: Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer 11:107-114, 2013
6. Rini BI, Garrett M, Poland B, et al: Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53:491-504, 2013
7. Rini BI, Cohen DP, Lu DR, et al: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773, 2011
8. Rini BI, Schiller JH, Fruehauf JP, et al: Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17:3841-3849, 2011
9. Jain L, Sissung TM, Danesi R, et al: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95, 2010
10. Rugo HS, Herbst RS, Liu G, et al: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483, 2005
11. O'Connor OA, Stewart AK, Vallone M, et al: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15:7085-7091, 2009
12. Mross K, Frost A, Steinbild S, et al: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658-2667, 2012
13. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88-94, 2013
14. Hurwitz HI, Dowlati A, Saini S, et al: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227, 2009
15. Kawashima A, Takayama H, Arai Y, et al: One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer 47:1521-1526, 2011
16. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
17. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
18. Tanaka C, O'Reilly T, Kovarik JM, et al: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602, 2008
19. Ratain MJ: Flushing oral oncology drugs down the toilet. J Clin Oncol 29:3958-3959, 2011
20. Sharma MR, Karrison TG, Kell B, et al: Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res 19:3059-3067, 2013
21. Wakelee HA, Lee JW, Hanna NH, et al: A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: Eastern Cooperative Oncology Group study E2501. J Thorac Oncol 7:1574-1582, 2012
22. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2011
23. Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47:2117-2127, 2011
24. Naito S, Tsukamoto T, Murai M, et al: Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: Final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 108:1813-1819, 2011
25. Procopio G, Verzoni E, Iacovelli R, et al: Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial. Br J Cancer 104:1256-1261, 2011
26. Matei D, Sill MW, Lankes HA, et al: Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A Gynecologic Oncology Group trial. J Clin Oncol 29:69-75, 2011
27. Gitlitz BJ, Moon J, Glisson BS, et al: Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: A Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835-1840, 2010
28. Nimeiri HS, Oza AM, Morgan RJ, et al: A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 117:37-40, 2010
29. Safarinejad MR: Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A phase II study. Urol Oncol 28:21-27, 2010
30. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27:4274-4280, 2009
31. Di Lorenzo G, Cartenì G, Autorino R, et al: Phase II study of sorafenib in patients with sunitinibrefractory metastatic renal cell cancer. J Clin Oncol 27:4469-4474, 2009
32. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
33. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289, 2009
34. Yau T, Chan P, Ng KK, et al: Phase 2 openlabel study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer 115:428-436, 2009
35. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
36. Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009
37. Llovet JM, Ricci S, Mazzaferro V, et al:. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
38. Steinbild S, Mross K, Frost A, et al: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97:1480-1485, 2007 (Pubitemid 350175850)
39. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300, 2006 (Pubitemid 46630787)
40. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006 (Pubitemid 46630627)
41. Nowak AK, Millward MJ, Creaney J, et al: A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 7:1449-1456, 2012
42. Motzer RJ, Hutson TE, Olsen MR, et al: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371-1377, 2012
43. Yi JH, Thongprasert S, Lee J, et al: A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study. Eur J Cancer 48:196-201, 2012
44. Barrios CH, Hernandez-Barajas D, Brown MP, et al: Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118:1252-1259, 2012
45. Gervais R, Hainsworth JD, Blais N, et al: Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 74:474-480, 2011
46. Novello S, Camps C, Grossi F, et al: Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 6:1260-1266, 2011
47. Moehler M, Mueller A, Hartmann JT, et al: An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemorefractory advanced gastric cancer. Eur J Cancer 47:1511-1520, 2011
48. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
49. O'Reilly EM, Niedzwiecki D, Hall M, et al: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15:1310-1319, 2010
50. Tomita Y, Shinohara N, Yuasa T, et al: Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166-1172, 2010
51. Bang YJ, Kang YK, Kang WK, et al: Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 29:1449-1458, 2011
52. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
53. Escudier B, Roigas J, Gillessen S, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokinerefractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075, 2009
54. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584- 3590, 2009
55. George S, Blay JY, Casali PG, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968, 2009
56. Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748, 2008
57. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
58. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
59. Socinski MA, Novello S, Brahmer JR, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008 (Pubitemid 351264362)
60. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007 (Pubitemid 350086483)
61. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006 (Pubitemid 43854967)
62. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
63. Sternberg CN, Hawkins RE, Wagstaff J, et al: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 49:1287-1296, 2013
64. van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886, 2012
65. Monk BJ, Mas Lopez L, Zarba JJ, et al: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562-3569, 2010
66. Hutson TE, Davis ID, Machiels JP, et al: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28:475-480, 2010
67. Sleijfer S, Ray-Coquard I, Papai Z, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126-3132, 2009
68. Lee JS, Hirsh V, Park K, et al: Vandetanib versus placebo in patients with advanced non- small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30:1114-1121, 2012
69. Leboulleux S, Bastholt L, Krause T, et al: Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 13:897-905, 2012
70. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066, 2011
71. Natale RB, Bodkin D, Govindan R, et al: Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 27:2523-2529, 2009
72. Heymach JV, Paz-Ares L, De Braud F, et al: Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415, 2008
73. Arnold AM, Seymour L, Smylie M, et al: Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25:4278-4284, 2007 (Pubitemid 47548568)
74. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
75. Tomita Y, Uemura H, Fujimoto H, et al: Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 47:2592-2602, 2011
76. Rini BI, Wilding G, Hudes G, et al: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468, 2009
77. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
78. Rixe O, Bukowski RM, Michaelson MD, et al: Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 8:975-984, 2007 (Pubitemid 47629888)
79. Demetri GD, Reichardt P, Kang YK, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302, 2013
80. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
81. Schoffski P, Elisei R, Müller S, et al: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30:358s, 2012 (suppl; abstr 5508)
82. Nosov DA, Esteves B, Lipatov ON, et al: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 30:1678-1685, 2012
83. Mulders P, Hawkins R, Nathan P, et al: Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study. Eur J Cancer 48:527-537, 2012
84. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
85. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
86. Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 30:2055-2062, 2012
87. Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377:914-923, 2011
88. Gradishar WJ, Krasnojon D, Cheporov S, et al: Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611-3619, 2009
89. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
90. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
91. Martín M, Ruiz A, Muñoz M, et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8:219-225, 2007 (Pubitemid 46291704)
92. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
93. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
94. Colevas AD, Setser A: The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 22:543s, 2004 (suppl; abstr 6098)
95. Amato R, Zhai J, Willis J, et al: A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 10:153-158, 2012
96. Escudier B, Rini BI, Hutson TE, et al: Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Eur Uro Suppl 11:e81, 2012
97. Rini BI, Melichar B, Ueda T, et al: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol 14:1233-1242, 2013
98. Motzer RJ, Nosov D, Eisen T, et al: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 31:3791-3799, 2013
99. Motzer RJ, Barrios CH, Kim TM, et al: Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31:285s, 2013 (suppl; abstr 4504)
100. Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 31:4067-4075, 2013
101. Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731, 2013
102. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
103. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
104. Hutson TE, Lesovoy V, Al-Shukri S, et al: Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial. Lancet Oncol 14:1287-1294, 2013
105. Edgerly M, Fojo T: Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100:240-242, 2008 (Pubitemid 351480535)
106. Iavarone M, Cabibbo G, Piscaglia F, et al: Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 54:2055-2063, 2011
107. Sternberg C, Bracarda S, Carteni G, et al: Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC): Final Italian results. European Cancer Conference 2013, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr 2707)
108. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
109. Elisei R, Schlumberger MJ, Müller SP, et al: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639-3646, 2013
110. Chang J: Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36:S11-S14, 2000
111. Brose MS, Nutting C, Jarzab B, et al: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 31:6s, 2013 (suppl; abstr 4)